Wilmington Pharmaceuticals

Wilmington Pharmaceuticals was a specialty pharmaceutical company focused on the development and commercialization of proprietary pharmaceutical products using the FDA's 505(b)(2) regulatory pathway. The company's lead product, Metozolv ODT (metoclopramide), was an orally disintegrating tablet formulation designed for patients with gastroesophageal reflux disease (GERD) and diabetic gastroparesis who have difficulty swallowing. Following the FDA approval of Metozolv ODT in 2009, the company entered into a definitive agreement with Salix Pharmaceuticals for the exclusive right to commercialize the product in the United States. The company was venture-backed by firms such as Pappas Ventures and Intersouth Partners before its primary assets were commercialized and the company became inactive.